Salestools LogoSalestools
Salestools LogoSalestools
Biotech

Zymergen

Zymergen raises $575M Series D at $3.2B valuation

$575M
Total Raised
Series D
Latest Round
2013
Founded
800+
Employees
5980 Horton Street, Emeryville, CA 94608
1 min read

Quick Facts

Valuation
$3.2B
Latest Round Size
$575M
Latest Round Date
February 2024

Zymergen: Series D Funding Round

Zymergen has successfully raised $575M in Series D funding, reaching a valuation of $3.2B.

Company Overview

Bio-based materials manufacturing

Funding Details

The Series D round was led by SoftBank Vision Fund, with participation from DCVC, True Ventures, Data Collective, Two Sigma Ventures.

Company Information

  • Headquarters: 5980 Horton Street, Emeryville, CA 94608
  • Founded: 2013
  • Employees: 800+
  • Category: Biotech

Investment

Zymergen plans to use the funds to accelerate product development, expand its team, and scale operations globally.

About the Investors

  • SoftBank Vision Fund: Verified investor in Series D
  • DCVC: Verified investor in Series D
  • True Ventures: Verified investor in Series D
  • Data Collective: Verified investor in Series D
  • Two Sigma Ventures: Verified investor in Series D

Key Investors

SoftBank Vision Fund
Lead Investor
Verified investor in Series D
DCVC
Investor
Verified investor in Series D
True Ventures
Investor
Verified investor in Series D
Data Collective
Investor
Verified investor in Series D
Two Sigma Ventures
Investor
Verified investor in Series D

Topics

verified(3080)real-funding(3080)series-d(248)biotech(108)zymergen(2)5980-horton-street(1)

About the Author

Editorial Team
Editorial Team
Curated funding news from verified sources

Related Company Reports

Biotech
Torl Biotherapeutics

Torl Biotherapeutics raises $96M Series C at $500M valuation

Torl Biotherapeutics raises $96M in Series C at $500M valuation. Antibody-based immunotherapies for cancer patients...

Editorial Team
Editorial Team
Oct 10, 2025
1 min read•$96M
Biotech
Nilo Therapeutics

Nilo Therapeutics raises $101M Series A at $450M valuation

Nilo Therapeutics raises $101M in Series A at $450M valuation. Developing therapies based on neuro-immunology research...

Editorial Team
Editorial Team
Oct 9, 2025
1 min read•$101M
Biotech
Arthrosi Therapeutics

Arthrosi Therapeutics raises $153M Series E at $800M valuation

Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...

Editorial Team
Editorial Team
Oct 8, 2025
1 min read•$153M